Supplementary Materials

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy

Ayelet Sivan, Leticia Corrales, Nathaniel Hubert, Jason B. Williams, Keston Aquino-Michaels, Zachary M. Earley, Franco W. Benyamin, Yuk Man Lei, Bana Jabri, Maria-Luisa Alegre, Eugene B. Chang, and Thomas F. Gajewski

Materials/Methods, Supplementary Text, Tables, Figures, and/or References

Download Supplement
  • Materials and Methods
  • Figs. S1 to S8
  • References
Table S1
Comparison of bacterial abundance between JAX and TAC mice, sham-, TAC-, and JAX-fed TAC mice at sequence level.
Table S2
Comparison of bacterial abundance between JAX and TAC mice, sham-, TAC-, and JAX-fed TAC mice at genus level.
Table S3
Univariate association testing between bacterial abundance and antigen-specific T cell infiltration across all permutation groups at sequence and genus levels.
Table S4
Comparison of bacterial abundance between TAC and Bifidobacterium-fed TAC mice at sequence and genus levels.
Table S5
Gene expression profiling results (Illumina microarray) comparing gene expression in DCs isolated from tumors of TAC, JAX, and Bifidobacterium-fed TAC mice.
Table S6
Gene expression profiling results (Illumina microarray) comparing gene expression in BM-DCs untreated or stimulated with Bifidobacterium in vitro.
Table S7
Primer sequences and probes (Roche Universal Probe Library) for qPCR validation of gene transcripts up-regulated by ≥1.5-fold in both JAX and Bifidobacterium-treated TACderived DCs relative to DCs from untreated TAC mice.